Literature DB >> 20875460

Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.

Soo-Yon Rhee1, Severine Margeridon-Thermet, Mindie H Nguyen, Tommy F Liu, Ron M Kagan, Bastian Beggel, Jens Verheyen, Rolf Kaiser, Robert W Shafer.   

Abstract

Drug resistance resulting from reverse transcriptase (RT) mutations is one of the main obstacles to successful hepatitis B virus (HBV) therapy. Indeed, HBV treatment guidelines recommend HBV genotypic resistance testing for patients receiving nucleos(t)ide RT inhibitors (N(t)RTIs) who develop virological failure. N(t)RTI-resistance mutations at 10 RT positions have been well characterized in phenotypic studies, however, data are lacking on the relative frequency of these mutations in N(t)RTI-treated and untreated individuals. There are also few published data on the extent of amino acid variation at most of the 344 positions of HBV RT and the extent to which this variation is influenced by N(t)RTI treatment. We retrieved 23,871 HBV RT sequences from GenBank and reviewed the published reports of these sequences to ascertain the number of individuals from whom the sequences were obtained, the N(t)RTI treatments of these individuals, and the year and region of virus sampling. We then used these data to populate a relational database we named HBVrtDB. As of July 2010, HBVrtDB contained 6811 sequences from 3869 individuals reported in 281 references. Among these 3869 individuals, 73% were N(t)RTI-naïve and 27% received one or more N(t)RTIs. Among the 10 well-characterized N(t)RTI-resistance mutations, L80I/V, V173L, L180M, A181T, T184S, S202G and M204I/V were significantly associated with treatment with lamivudine, an l-nucleoside analog, and A181S/T/V and N236T were significantly associated with treatment with adefovir, an acyclic nucleoside phosphonate. A similar analysis of ten additional less well-characterized resistance mutations demonstrated a significant association with N(t)RTI treatment for four of the mutations: L82M, S85A, A200V, and Q215S. We also created an interactive program, HBVseq, to enable users to identify mutations in submitted sequences and retrieve the prevalence of these mutations in HBVrtDB according to genotype and N(t)RTI treatment. HBVrtDB and HBVseq are available at http://hivdb.stanford.edu/HBV/releaseNotes/.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20875460      PMCID: PMC4374605          DOI: 10.1016/j.antiviral.2010.09.012

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  18 in total

Review 1.  Naturally occurring variants of hepatitis B virus.

Authors:  S Günther; L Fischer; I Pult; M Sterneck; H Will
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

2.  Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries.

Authors:  R W Shafer; D R Jung; B J Betts
Journal:  Nat Med       Date:  2000-11       Impact factor: 53.440

Review 3.  HBV drug resistance: mechanisms, detection and interpretation.

Authors:  Tim Shaw; Angeline Bartholomeusz; Stephen Locarnini
Journal:  J Hepatol       Date:  2006-01-19       Impact factor: 25.083

Review 4.  Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.

Authors:  Anna S Lok; Fabien Zoulim; Stephen Locarnini; Angeline Bartholomeusz; Marc G Ghany; Jean-Michel Pawlotsky; Yun-Fan Liaw; Masashi Mizokami; Carla Kuiken
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

5.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

6.  Under construction: classification of hepatitis B virus genotypes and subgenotypes.

Authors:  Stephan Schaefer; Lars Magnius; Helene Norder
Journal:  Intervirology       Date:  2009-09-29       Impact factor: 1.763

7.  SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.

Authors:  Lilly K W Yuen; Anna Ayres; Margaret Littlejohn; Danielle Colledge; Andrew Edgely; William J Maskill; Stephen A Locarnini; Angeline Bartholomeusz
Journal:  Antiviral Res       Date:  2006-12-22       Impact factor: 5.970

8.  Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

Authors:  K Das; X Xiong; H Yang; C E Westland; C S Gibbs; S G Sarafianos; E Arnold
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 9.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.

Authors:  Emmet B Keeffe; Douglas T Dieterich; Steven-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias
Journal:  Clin Gastroenterol Hepatol       Date:  2008-08-23       Impact factor: 11.382

10.  HepSEQ: International Public Health Repository for Hepatitis B.

Authors:  Saravanamuttu Gnaneshan; Samreen Ijaz; Joanne Moran; Mary Ramsay; Jonathan Green
Journal:  Nucleic Acids Res       Date:  2006-11-27       Impact factor: 16.971

View more
  21 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 2.  Antiviral therapies: focus on hepatitis B reverse transcriptase.

Authors:  Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

3.  Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naïve and Treated Indonesian Patients Infected with Hepatitis B Virus.

Authors:  Widya Wasityastuti; Yoshihiko Yano; Dewiyani Indah Widasari; Laura Navika Yamani; Neneng Ratnasari; Didik Setyo Heriyanto; Rina Okada; Toshihito Tanahashi; Yoshiki Murakami; Takeshi Azuma; Yoshitake Hayashi
Journal:  Kobe J Med Sci       Date:  2016-06-16

4.  Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots.

Authors:  Eleftherios Michailidis; Kamlendra Singh; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos
Journal:  Int J Curr Chem       Date:  2011-10

5.  Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies.

Authors:  Jing Li; Yun Du; Xian Liu; Qian-cheng Shen; Ai-long Huang; Ming-yue Zheng; Xiao-min Luo; Hua-liang Jiang
Journal:  Acta Pharmacol Sin       Date:  2012-12-03       Impact factor: 6.150

6.  Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.

Authors:  Samir Aoudjane; Mas Chaponda; Antonio Adrián González Del Castillo; Jemma O'Connor; Marc Noguera; Apostolos Beloukas; Mark Hopkins; Saye Khoo; Joep J van Oosterhout; Anna Maria Geretti
Journal:  Clin Infect Dis       Date:  2014-08-06       Impact factor: 9.079

Review 7.  Hepatitis B virus nuclear export elements: RNA stem-loop α and β, key parts of the HBV post-transcriptional regulatory element.

Authors:  Chun Shen Lim; Chris M Brown
Journal:  RNA Biol       Date:  2016-03-31       Impact factor: 4.652

8.  Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent: antiviral resistance mutations and predictive factors of treatment response.

Authors:  Ashrafali Mohamed Ismail; Prasanna Samuel; Jeyamani Ramachandran; Chundamannil Eapen Eapen; Rajesh Kannangai; Priya Abraham
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

9.  Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.

Authors:  Severine Margeridon-Thermet; Evguenia S Svarovskaia; Farbod Babrzadeh; Ross Martin; Tommy F Liu; Mary Pacold; Elizabeth C Reuman; Susan P Holmes; Katyna Borroto-Esoda; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

10.  HBVdb: a knowledge database for Hepatitis B Virus.

Authors:  Juliette Hayer; Fanny Jadeau; Gilbert Deléage; Alan Kay; Fabien Zoulim; Christophe Combet
Journal:  Nucleic Acids Res       Date:  2012-11-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.